Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity

Seminars in Ophthalmology

Volumn 29, Issue 2, 2014, Pages 108-113

  Erol, Muhammet Kazim ^a   Ozdemir, Ozdemir ^b   Coban, Deniz Turgut ^a   Ceran, Basak Bostanci ^a   Bulut, Mehmet ^a  

^a Antalya Education and Research Hospital   (Turkey)

^b ZEKAI TAHIR BURAK WOMEN S HEALTH EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Central serous chorioretinopathy; Multifocal choroiditis; Myopia; Punctate inner choroidopathy

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; AUTOFLUORESCENCE; CENTRAL SEROUS RETINOPATHY; CHOROIDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EYE EXAMINATION; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; FUNDUS CAMERA; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTOTOXICITY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; EYE DISEASE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; CHOROIDITIS; EYE DISEASES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; MYOPIA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 84896694798     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2013.839716     Document Type: Article

References (31)

1. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004;137:496-503.
2. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986;93:1169-176.
3. Postel EA, Pulido JS, Byrnes GA, et al. Long-term followup of iatrogenic phototoxicity. Arch Ophthalmol 1998; 116(6):753-757.
4. Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur J Ophthalmol 2010; 20(5):955-958.
5. Ozdek S, Ozmen MC, Tufan HA, et al. Photodynamic therapy for best disease complicated by choroidal neovascularization in children. J Pediatr Ophthalmol Strabismus 2012;49(4):216-221.
6. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-114.
7. Hawkins BS, Bressler NM, Bressler SB, et al. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9. Arch Ophthalmol 2004;122: 1597-611.
8. Lee YA, Ho TC, Chen MS, et al. Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. Eye 2009;23:645-651.
9. Ruiz-Oliva F, Cortes J. Verteporfin in Photodynamic Therapy (VIP) Study group. Ophthalmology 2002;109:1043- 1044.
10. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26(4):383-390.
11. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113(3):363-372.
12. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 444.
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006;355(14):1419-431.
14. Gedik Oǧuz Y, Batioǧlu F, Özmert E. The results of intravitreal ranibizumab injection for choroidal neovascularization from causes other than age-related macular degeneration. Retina Vitreus 2011;19(4):231-236.
15. Chang LK, Spaide RF, Brue C, et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-945.
16. Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye 2010;24: 203-213.
17. Heier JS, Brown D, Ciulla T, et al. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 2011;118:111-118.
18. Sawa M, Gomi F, Tsujikawa M, et al. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol 2009;148:584-590.
19. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008;146:410-416.
20. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol. 2009;93:448-451.
21. Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina 2012;32(7):1250-259.
22. Monés J, Biarnés M, Trindade F, Casaroli-Marano R. FUSION regimen: Ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol 2012;250:1737-1744.
23. Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond) 2011;25(12):1617-621.
24. Troutbeck R, Bunting R, van Heerdon A, et al. Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes. Clinical and Experimental Ophthalmology 2012;40: 67-72.
25. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4):566-583.
26. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
27. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143(6):977-983.
28. Mandal S, Sinha S, Abbas Z, Vankatesh P. Intravitreal bevacizumab for subfoveal choroidal neovascularization complicating active central serous chorioretinopathy. Indian J Ophthalmol 2011;59(4):338-339.
29. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90: 923-926.
30. Tabandeh H, Flynn HWJ, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-067.
31. Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 2012.Jul 1; 43(4):328-334.